Abena is a Danish, family-owned company manufacturing incontinence products, health care products, and baby diapers. Besides our own production in Denmark, Sweden, and France we also supply a wide range of sourced products such as; gloves, body wash, skin care, wound care, food service and paper.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

news image

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More

MedTech

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

news image

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

news image

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

news image

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More
news image

Cell and Gene Therapy, Industrial Impact

BIO-TECHNE ANNOUNCES COMPLETION OF AND GENE THERAPY CATAPULT ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM

Bio-Techne Corporation | March 20, 2023

Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technolog...

Read More
news image

MedTech

AEGLEA BIOTHERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR PEGZILARGINASE

Aeglea BioTherapeutics, Inc. | August 19, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that a Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency has been submitted to and successfully validated by the European Medicines Agency. The MAA was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East. <...

Read More
news image

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More
news image

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us